A. Villanueva, Hepatocellular carcinoma. N. Engl. J. Med. 380, 1450–1462 (2019)

Article  CAS  PubMed  Google Scholar 

J.C. Nault, A. Villanueva, Biomarkers for hepatobiliary cancers. Hepatology 73(Suppl 1), 115–127 (2021)

Article  PubMed  Google Scholar 

U. Harkus et al., Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data. Semin. Cancer Biol. 86, 799–815 (2022)

S.M. Kalasekar, I. Garrido-Laguna, K.J. Evason, Immune checkpoint inhibitors in combinations for hepatocellular carcinoma. Hepatology 73, 2591–2593 (2021)

Article  PubMed  Google Scholar 

A. Huang, et al., Targeted therapy for hepatocellular carcinoma. Signal Transduct. Target Ther. 5, 146 (2020)

Article  MathSciNet  PubMed  PubMed Central  Google Scholar 

M. Pinter, B. Scheiner, M. Peck-Radosavljevic, Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut 70, 204–214 (2021)

Article  CAS  PubMed  Google Scholar 

E.N. De Toni, Immune checkpoint inhibitors: use them early, combined and instead of TACE? Gut 69, 1887–1888 (2020)

Article  PubMed  Google Scholar 

T.F. Greten, et al., Targeted and immune-based therapies for hepatocellular carcinoma. Gastroenterology 156, 510–524 (2019)

Article  PubMed  Google Scholar 

K. Shigeta, et al., Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. Hepatology 71, 1247–1261 (2020)

Article  CAS  PubMed  Google Scholar 

K. Shigeta, et al., Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. J. Immunother. Cancer 8, e001435 (2020)

S.J. Casak, et al., FDA approval summary: atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma. Clin. Cancer. Res. 27, 1836–1841 (2021)

Article  CAS  PubMed  Google Scholar 

S. Qin, et al., Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J. Hematol. Oncol. 12, 27 (2019)

Article  PubMed  PubMed Central  Google Scholar 

M.E. Couch, et al., Alteration of cellular and humoral immunity by mutant p53 protein and processed mutant peptide in head and neck cancer. Clin. Cancer. Res. 13, 7199–7206 (2007)

Article  CAS  PubMed  Google Scholar 

E. Dai, et al., Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Mol. Cancer 20, 171 (2021)

Article  CAS  PubMed  PubMed Central  Google Scholar 

X.M. Shao, et al., HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade. Ann. Oncol. 33, 728–738 (2022)

S.E. Lee, et al., Improvement of STING-mediated cancer immunotherapy using immune checkpoint inhibitors as a game-changer. Cancer Immunol. Immunother. 71, 1–14 (2022)

E.B. Ellingsen, et al., Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials. J. Immunother. Cancer 10, e004345 (2022)

A. Rooney, et al., Risk of SARS-CoV-2 breakthrough infection in vaccinated cancer patients: a retrospective cohort study. J. Hematol. Oncol. 15, 67 (2022)

Article  CAS  PubMed  PubMed Central  Google Scholar 

E. Fang, et al., Advances in COVID-19 mRNA vaccine development. Signal Transduct. Target Ther. 7, 94 (2022)

S. Qin, et al., mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct. Target Ther. 7, 166 (2022)

Article  CAS  PubMed  PubMed Central  Google Scholar 

W. Mey, et al., RNA in cancer immunotherapy: unlocking the potential of the immune system. Clin. Cancer. Res. 28, 3929–3939 (2022)

J. Wei, A.M. Hui, The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines. Cancer Treat. Rev. 107, 102405 (2022)

Article  CAS  PubMed  PubMed Central  Google Scholar 

A.J. Barbier, et al., The clinical progress of mRNA vaccines and immunotherapies. Nat. Biotechnol. 40, 840–854 (2022)

T. Huang, et al., Lipid nanoparticle-based mRNA vaccines in cancers: current advances and future prospects. Front. Immunol. 13, 922301 (2022)

Article  CAS  PubMed  PubMed Central  Google Scholar 

C.L. Lorentzen, et al., Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 23, e450–e458 (2022)

Article  CAS  PubMed  PubMed Central  Google Scholar 

N. Pardi, et al., mRNA vaccines - a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261–279 (2018)

Article  CAS  PubMed  PubMed Central  Google Scholar 

M. Sebastian, et al., Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive(R)) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer 14, 748 (2014)

Article  PubMed  PubMed Central  Google Scholar 

K.A. Batich, et al., Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination. Clin. Cancer. Res. 23, 1898–1909 (2017)

Article  CAS  PubMed  PubMed Central  Google Scholar 

J. Li, et al., Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer. Int. J. Cancer 134, 1683–1694 (2014)

Article  CAS  PubMed  Google Scholar 

H. Kubler, et al., Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. J. Immunother. Cancer 3, 26 (2015)

Z. Tang, et al., GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic. Acids Res. 47, W556–W560 (2019)

Article  CAS  PubMed  PubMed Central  Google Scholar 

T. Li, et al., TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 77, e108–e110 (2017)

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

S. Hanzelmann, R. Castelo, J. Guinney, GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinf. 14, 7 (2013)

G. Bindea, et al., Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782–795 (2013)

Article  CAS  PubMed  Google Scholar 

P. Charoentong, et al., Pan-cancer Immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 18, 248–262 (2017)

Article  CAS  PubMed  Google Scholar 

K. Yoshihara, et al., Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013)

Article  ADS  PubMed  Google Scholar 

D.M. Wolf, et al., Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity. PLoS One 9, e88309 (2014)

Article  ADS  PubMed  PubMed Central  Google Scholar 

P. Langfelder, S. Horvath, WGCNA: an R package for weighted correlation network analysis. BMC Bioinf. 9, 559 (2008)

Article  Google Scholar 

A. Kamburov, et al., The consensusPathDB interaction database: 2013 update. Nucleic. Acids Res. 41, D793–800 (2013)

Article  CAS  PubMed  Google Scholar 

X. Huang, et al., Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development. Mol. Cancer 20, 44 (2021)

R.L. Camp, M. Dolled-Filhart, D.L. Rimm, X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin. Cancer. Res. 10, 7252–7259 (2004)

Article  CAS  PubMed  Google Scholar 

Y.R. Miao, et al., ImmuCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy. Adv. Sci. (Weinh) 7, 1902880 (2020)

Article  CAS  PubMed  Google Scholar 

G. Zhang, et al., mRNA vaccines in disease prevention and treatment. Signal Transduct. Target Ther. 8, 365 (2023)

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

X. Huang, et al., Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development. Mol. Cancer 20, 50 (2021)

Article  CAS  PubMed  PubMed Central  Google Scholar 

X. Huang, et al., Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine. Mil. Med. Res. 9, 53 (2022)

T.Y. Tang, et al., mRNA vaccine development for cholangiocarcinoma: a precise pipeline. Mil. Med. Res. 9, 40 (2022)

X. Huang, G. Zhang, T. Liang, Subtyping for pancreatic cancer precision therapy. Trends Pharmacol. Sci. 43, 482–494 (2022)

Article  CAS  PubMed  Google Scholar 

J. Seo, et al., Fatty-acid-induced FABP5/HIF-1 reprograms lipid metabolism and enhances the proliferation of liver cancer cells. Commun. Biol. 3, 638 (2020)

Article